Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220898 | 0.83 | KDM4E (0.40) | ALDH1A1SMN1; SMN2KDM4EMAPTMAP2K1 | |
| SCHEMBL219751 | 0.80 | MAP2K1 (0.54) | MAP2K1 | |
| SCHEMBL28821845 | 0.77 | L3MBTL1 (0.39) | ALDH1A1SMN1; SMN2KDM4EMAPTMAP2K1 | |
| SCHEMBL218952 | 0.77 | MAP2K1 (0.58) | MAP2K1 | |
| SCHEMBL219587 | 0.76 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4EMAPTKMT2A | |
| SCHEMBL18519079 | 0.73 | LMNA (0.39) | ALDH1A1SMN1; SMN2KDM4EMAPTGAA | |
| SCHEMBL16322852 | 0.73 | MAP2K1 (0.49) | ALDH1A1KDM4EMAPTMAP2K1KMT2A | |
| SCHEMBL21136487 | 0.73 | TP53 (0.38) | ALDH1A1KDM4EMAPTKMT2AGAA | |
| SCHEMBL14632018 | 0.72 | MAP2K1 (0.46) | MAP2K1LMNAHTT | |
| SCHEMBL29192381 | 0.71 | HTT (0.35) | ALDH1A1SMAD3APAF1SMN1; SMN2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | claimed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088783-B2 | MAPK/ERK kinase inhibitors | DONG QING (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-7943626-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696218-B2 | Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase | TAKEDA SAN DIEGO, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2091941-A2 | MAPK/ERK KINASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140553-A2 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190261-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK4, MAPK6 | ALDH1A1 1803/4885SMAD3 843/4885APAF1 1115/4885 |
| US-20100204471-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885SMAD3 802/4885APAF1 1260/4885 |
| US-20080125437-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | ALDH1A1 2921/4885SMAD3 802/4885APAF1 1260/4885 |
| US-20100113413-A1 | MAPK/ERK Kinase Inhibitors | MAPK1, MAPK6, MAPK4 | ALDH1A1 1553/4885SMAD3 995/4885APAF1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.